The “grand experiment” of the Affordable Medicines Facility-malaria (AMFm) — a pilot program that aims to get artemisinin-based combination therapies (ACTs) into rural areas of several African nations — “seems likely to end, its successes underrated and potential improvements not yet explored,” a Nature editorial says. In October, “an independent evaluation found that it had performed remarkably well on the main benchmarks of success, increasing the number of outlets stocking ACTs and lowering prices,” but last week “the Global Fund to Fight AIDS, Tuberculosis and Malaria decided to end the AMFm as a stand-alone program, by integrating it into the fund’s core system for awarding malaria-control grants to countries,” the editorial notes, adding, “This integration probably spells the end for AMFm, because there will be no new money for the program after the end of next year.”
IRIN examines the controversy surrounding the Affordable Medicines Facility-malaria (AMFm), writing, “The argument over the way it operates has reignited ahead of a board meeting of the [Global Fund to Fight AIDS, Tuberculosis and Malaria] on 14-15 November, which is due to assess the success of the project and its reliance on private sector providers.” The news service reports on an evaluation of AMFm published recently in the Lancet and another paper by Oxfam criticizing the facility. The Global Fund Board, which administers AMFm, “is meeting in nine days to decide whether AMF has worked as was intended, and whether it should be continued, scaled up, or abandoned altogether,” IRIN writes (11/5).
The BMJ examines the history of fraud allegations against the Global Fund to Fight AIDS, Tuberculosis and Malaria and the organization’s ongoing reform efforts. “Most observers agree that after a honeymoon first decade, the Global Fund had grown so big, and the economic climate and attitudes to diseases such as AIDS have changed so dramatically, that more rigor and efficiency was needed, fraud or no fraud,” BMJ writes. The Fund is expected to appoint a new director “and a new funding model, to be announced on November 15, [which] are supposed to get things back on track” (Arie, 11/12).
BBC News examines “a worrying drop in the effectiveness of the artemisinin-based drugs” against malaria along the Cambodian-Thai border, and how clinics are attempting to combat the trend by offering monetary incentives to patients to complete treatment regimens. “Thanks to the efforts of health workers … , and the widespread availability of treatment, malaria still only kills a handful of people in Thailand each year,” according to the BBC. “The focus now is on trying to monitor and contain artemisinin drug resistance into a few hotspots, prolonging the drug’s effective lifespan globally until alternative treatments are available,” the news service writes, adding, “Africa’s hopes of maintaining its progress rests firmly on South East Asia’s efforts.” Fatoumata Nafo-Traore, executive director of Roll Back Malaria and the former health minister of Mali, said if drug-resistant malaria reached Africa, it would be a “massive crisis” because there is not an alternative drug to the usually highly effective artemisinin-based drugs, according to BBC (Fisher, 11/22).
“Many of Africa’s anti-malaria drugs are fake or of poor quality, weakening a crucial battle against the world’s deadliest disease, a new investigation has found,” GlobalPost reports, adding, “Many of the drugs — even those approved by the World Health Organization — are Chinese fakes or low-quality variants that failed quality tests, according to two new studies released today” (Conway-Smith, 7/10). “Two studies published in Research and Reports in Tropical Medicine suggested manufacturing problems, rather than counterfeiting, may be to blame for these substandard drugs in low- and middle-income countries around the world,” Agence France-Presse writes (7/10). Writing in a Business Day opinion piece published on Tuesday, “Roger Bate, lead author of the studies and a scholar at the conservative American Enterprise Institute, warned of ‘unthinkable’ public health consequences from drug resistance,” GlobalPost notes.
Cuban Company's Sales Of Larvicides To Fight Malaria-Carrying Mosquitoes In Africa Continue Despite U.N. Concern, Miami Herald Reports
The Cuban state-owned company Labiofam “is increasing sales of its mosquito larvicides to fight malaria in Africa, despite cautions by U.N. experts that such products have limited use and are not the most cost-effective method of attacking the disease,” the Miami Herald reports. The company’s website “says its larvicide Griselesf is used in anti-malaria programs in Ghana, Angola, Gambia, Tanzania, Nigeria, Burkina Faso, Equatorial Guinea, and Zambia,” according to the newspaper.
“The World Health Organization heralded major gains Tuesday in the fight against malaria, one of the developing world’s biggest killers, but warned universal access to treatment remains elusive,” Agence France-Presse reports, noting, “The assessment came on the eve of World Malaria Day,” observed Wednesday and “designed to shine the light on the mosquito-borne parasite that killed 655,000 people in 2010, including 560,000 children under five” (4/24). “A massive acceleration in the global distribution of mosquito nets, the expansion of programs to spray the insides of buildings with insecticides, and an increase in access to prompt antimalarial treatment has brought down malaria mortality rates by more than a quarter worldwide, and by one-third in Africa since 2000,” but “simply maintaining current rates of progress will not be enough to meet global targets for malaria control,” the agency writes in a news release (4/24).
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization’s future. She writes, “It’s been only seven weeks since banker Gabriel Jaramillo took over as general manager of the [fund], but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine.” She continues, “Jaramillo, former chair and chief executive of Sovereign Bank, brings a tougher attitude to the organization.”
‘Complacency Is Dangerous’ In Global HIV/AIDS Fight: A Lancet Editorial is critical of UNAIDS Executive Director Michel Sidibe’s statement in the annual UNAIDS reportÂ that “We have halted and begun to reverse the epidemic.” The editorial states, “These words, from the head of a U.N. agency, are reckless and premature, and…
An experimental vaccine was found to promote immune responses to malaria in young children in Mali, Reuters reports. According to the news service, “The vaccine, which uses an immune system booster called an adjuvant from British drugmaker GlaxoSmithKline, targets the malaria parasite as it is actively infecting red blood cells and causing fever and illness” (Steenhuysen, 2/3).